Medtronic Starts International Market Launch And U.S. Clinical Trial Of Endurant Stent Graft

Expanding the application of endovascular aortic repair around the world, Medtronic, Inc. (NYSE: MDT), announced two major milestones: the international market launch of the Endurant Abdominal Stent Graft System and the first implants of this next-generation medical device in the U.S. clinical trial. International Market Launch The Endurant Stent Graft was CE (Conformité Européene) marked last week, and Medtronic will begin commercialization in mid-July.

More: continued here

Filed under: Cardiovascular on July 8th, 2008